Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“WCLC26: REZILIENT 3 in 1L EGFR exon20+ NSCLC.
Zipalertinib + chemo vs chemo:
- PFS 14.5 vs 8.5 mo
- HR 0.50 (95% CI 0.34–0.73)
- P=0.00015
- ORR 65.0% vs 40.3%
- DoR 14.2 vs 9.9 mo
Baseline brain mets subgroup: PFS HR 0.38. Worth watching, but descriptive – not definitive.
OS remains immature:
- HR 0.72 (95% CI 0.42–1.23)
- medians not reached
- follow-up 10.9 mo
- 64.2% crossover to zipalertinib
Trade-off: grade ≥3 TRAEs 80.7% vs 40.4%, largely cytopenias during platinum.
Bottom line: highly active 1L option, but with a substantial hematologic toxicity burden.”
This also can be interesting:
REZILIENT3 Trial: Major Positive Phase 3 Result in Exon 20 NSCLC
